A Phase 1 Study of Carfilzomib-Thalidomide-Dexamethasone in Patients with Relapsed/Refractory AL Amyloidosis - Catalyst Trial Results
Mamta Garg(Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo), Ashutosh Wechalekar(University College Hospital), Jamie B. Oughton, Julian D. Gillmore(Alnylam Pharmaceuticals (United States)), Bhuvan Kishore(National Health Service), Sarah Brown(University of Leeds), Matthew Jenner(University Hospital Southampton NHS Foundation Trust), Alexandra Pitchford(University of Leeds), Sajitha Sachchithanantham(The Royal Free Hospital), Andrew Hall(University of Leeds), Helen J. Lachmann(Royal Free London NHS Foundation Trust), Shameem Mahmood(The Royal Free Hospital), Louise Flanagan(University of Leeds)
Cited by 5
Related Papers
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
|New England Journal of Medicine|2021|1.7k
Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases
|European Heart Journal|2021|1.1k
Systemic amyloidosis
|The Lancet|2015|984